AstraZeneca (AZN) said Wednesday that an interim analysis of the phase 3 trial of its experimental therapy, camizestrant, combined with a cyclin-dependent kinase inhibitor showed statistically significant and clinically meaningful improvement in progression-free survival in certain breast cancer patients compared to standard of care.
Although key secondary endpoints such as time-to-second disease progression and overall survival were not fully mature, the combination therapy showed a trend toward improvement, the company said.
The drugmaker said the trial will continue to assess secondary endpoints as planned.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。